This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Amazon Technologies, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Gil Sadeh: Innovator in Immunogenicity Prediction
Introduction
Gil Sadeh is a prominent inventor based in Herzliya, Israel. He has made significant contributions to the field of immunogenicity prediction, particularly in the context of tumor-specific neoantigens. With a total of 2 patents to his name, Sadeh's work is paving the way for advancements in cancer treatment and personalized medicine.
Latest Patents
Sadeh's latest patents include a deep learning model for predicting tumor-specific neoantigen MHC class I or class II immunogenicity. This innovative method allows for the prediction of MHC class I or class II binding affinity and assesses the likelihood that a tumor-specific neoantigen will be presented by MHC proteins on a cell surface. Another notable patent focuses on immunogenic response prediction based on major histocompatibility complex (MHC) data. This system utilizes training data to identify peptides and MHC molecules, updating a model to determine the probability of an immunogenic response.
Career Highlights
Gil Sadeh is currently employed at Amazon Technologies, Inc., where he continues to develop cutting-edge technologies in the field of immunology. His expertise in deep learning and immunogenicity has positioned him as a key player in the research and development of predictive models that can enhance cancer therapies.
Collaborations
Sadeh collaborates with various professionals in his field, including his coworker Layne Christopher Price. Their combined efforts contribute to the advancement of innovative solutions in immunogenicity prediction.
Conclusion
Gil Sadeh's work in the realm of immunogenicity prediction is instrumental in the fight against cancer. His patents reflect a commitment to leveraging technology for medical advancements, ultimately aiming to improve patient outcomes.